NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00041197,Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery,https://clinicaltrials.gov/study/NCT00041197,,COMPLETED,This randomized phase III trial is studying imatinib mesylate to see how well it works compared to placebo in treating patients with primary gastrointestinal stromal tumor that has been completely removed by surgery. Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for patients with primary gastrointestinal stromal tumor that has been completely removed by surgery.,NO,Gastrointestinal Stromal Tumor,DRUG: imatinib mesylate|OTHER: placebo|OTHER: laboratory biomarker analysis,"Recurrence-free survival (RFS), An O'Brien-Fleming bound will be used to stop the trial early for superiority of the STI571 arm., From date of resection to the date of first observation of recurrence, assessed up to 10 years","Safety as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, Safety analysis will consist of routine tabulations, detailed documentation concerning all adverse events, detailed documentation of any unusual events, and any special reports, analyses, or tabulations requested by the DSMC., Up to 5 years|Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes, Up to 10 years",,National Cancer Institute (NCI),,ALL,"ADULT, OLDER_ADULT",PHASE3,732,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",NCI-2012-02930|Z9001|CDR0000069452|U10CA076001,2002-06,2007-04,,2003-01-27,,2013-07-16,"American College of Surgeons Oncology Group, Durham, North Carolina, 27705, United States",
